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Background: The goal of this report was to compare clinical outcomes for elderly patients with cervical
cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy (IM-CCRT) or two-
dimensional radiotherapy (2D-CCRT).
Methods: Sixty patients older than 75 years were treated with CCRT (30 with 2D-CCRT, and 30 with IM-
CCRT) in Mackay Memorial Hospital, Taipei, Taiwan with Eastern Cooperative Oncology Group perfor-
mance status 0e1. Retrospectively, treatment toxicities were graded weekly according to the NCI (Na-
tional Cancer Institute) Common Toxicity Criteria version 3.0 and RTOG (Radiation Therapy Oncology
Group) criteria. The Kaplan and Meier method compared with the log-rank test was used for disease-free
survival (DFS) and overall survival (OS).
Results: The median follow up duration of all patients was 41.7 months (range, 1e101 months). There
were no statistical differences in histological type, The International Federation of Gynecology and Ob-
stetrics stage, performance status, and cycles of chemotherapy between these two groups (p ¼ 0.554,
p ¼ 0.793, p ¼ 0.796, and p ¼ 0.161, respectively). The mean treatment duration was signiﬁcantly longer
for the IM-CCRT-group (66.1 days vs. 51.7 days, p < 0.05). The local recurrence and distant metastasis
were signiﬁcantly lower for the IM-CCRT-group (p ¼ 0.023 and p ¼ 0.006, respectively). Acute gastro-
intestinal toxicities tended to be more signiﬁcant in patients who received IM-CCRT (2D-CCRT vs. IM-
CCRT: Grade 2 ¼ 23% vs. 27%, Grade 3 ¼ 23% vs. 37%, p ¼ 0.001, respectively). The 3-year actuarial OS
of the 2D-CCRT-group and IM-CCRT-group were 70.2% and 78.8%, respectively (p ¼ 0.689). The 3-year
DFS of the 2D-CCRT-group and IM-CCRT-group were 73.4% and 100%, respectively (p ¼ 0.014).
Conclusion: The use of IM-CCRT was associated with equivalent compliance and encouraging preliminary
clinical results compared to 2D-CCRT.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The efﬁcacy of cisplatin-based concurrent chemo-radiotherapy
(CCRT) over radiotherapy alone in cervical cancers has been well
documented for more than 15 years.1 CCRT was suggested forre that they have no conﬂicts
emorial Hospital, Radiation
aipei 104, Taiwan.
tric Emergency & Critical Care Med
es/by-nc-nd/4.0/).women who have locoregionally advanced cervical cancer that is
conﬁned to the pelvis and for women who require post-
hysterectomy radiotherapy for high-risk disease.1
Cervical cancer typically occurs in the 5th and 6th decades of life;
< 20% of patients are older than 75 years2. Old aged patients’
tolerance may be compromised because of their general perfor-
mance status, comorbidities, and general concepts about short re-
sidual life. Therefore, administration of concurrent chemotherapy
may increase the cost and complexity of treatment for elderly
patients.icine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
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is suggested that chemoradiation should be considered in elderly
patients with invasive cervical cancer with decreased mortality
compared with conventional radiotherapy alone4.
Recently, standard radiotherapy treatment planning for cervical
cancer has been shifting from conventional two-dimensional (2D)
planning to 3D planning in order to achieve appropriate coverage of
the target within sufﬁcient dose and optimal sparing of organs at
risk5.
Intensity-modulated radiotherapy (IMRT) is a promising form of
3D-conforming radiotherapy that produces a highly conformal
dose closer to the target volumes and normal pelvic tissues (i.e.,
small bowel, bladder, rectum) are relatively spared. Treatment
related toxicities might be reduced in patients with uterine cervical
cancer by using IMRT alone6,7. At the present time, there is not
enough data to support routine use of IMRT for cervical cancer with
CCRT, especially for the elderly.
Therefore, we reviewed our experience in elderly patients (aged
 75 years) with good performance status treated in Mackay Me-
morial Hospital, Taipei, Taiwan from January 1, 2000 to June 6, 2013,
and analyzed their survivals and compliance after CCRT with con-
ventional 2D (2D-CCRT-group) versus IMRT (IM-CCRT-group),
retrospectively.2. Materials and Methods
From January 2000 to June 2013, there were 1250 cervical
cancers treated with radiotherapy in Mackay Memorial Hospital.
Sixty biopsy proven cervical cancers in patients aged  75 years
with Eastern Cooperative Oncology Group performance status 0e1
after complete history, physical examination including cystoscopy
and proctoscopy, and laboratory studies had received concurrent
chemoradiotherapy (CCRT) with weekly intravenous cisplatin,
retrospectively. The Institute Review Board of Mackay Memorial
Hospital (MMH-I-S-157 and MMH-I-S-434) approved this study.
2D Radiotherapy was planned by using a Pinnacle Treatment
Planning System (Philips Healthcare, Madison, WI, USA) or Eclipse
IMX Planning System (Varian Associates, Inc., Palo Alto, CA, USA)
and delivered by a linear accelerator (Clinac1800 or IX, Varian As-
sociates, Inc., Palo Alto, CA, USA; Precise, Elekta Inc., Stockholm,
Sweden) to target volumes including the primary lesion, the pelvic
nodes and the common iliac lymph nodes. Paraaortic lymph nodes
were included if metastases were detected in image examination.
2D Radiotherapy was delivered by an initial four-ﬁeld box tech-
nique followed by a parallel-opposed technique at the time
brachytherapy was begun. Margins of the anterior-posterior ﬁelds
were the upper margin of L4e5 (superiorly), the lower margin of
the obturator foramen or the lowest extension of the disease
(inferiorly), and 1.5e2.0 cm beyond lateral margins of true bony
pelvis. For the lateral ﬁelds, the anterior margin was the anterior
edge of the pubic symphysis. The posterior margins at the S2eS3
interspaces were used.
A total of 45e50.4 Gy to the isocenter was prescribed in 25e28
fractions by 10e15 MV X-ray at 320 cGy/min. A supplemental dose
of 5.4e9 Gywas given to the parametrium areawhen necessary. For
patients with positive paraaortic lymph node metastasis, periaortic
node irradiation was irradiated with 45 Gy of extended ante-
roposterior and posteroanterior ﬁelds in conjunction with whole
pelvic radiation. High dose intracavitary brachytherapy was given
following the initial 30e40 Gy of whole pelvis irradiation. Mean-
while, the RT plan was changed in anteroposterior/posteroanterior
ﬁelds to achieve the intended prescription dose of 45e59.4 Gy. The
designed prescription dose was delivered at 1.8e2.0 Gy daily frac-
tion, ﬁve fractions per week.IMRT was delivered by a 6e10 MV linear accelerator (Precise, or
VMAT, Elekta Inc.) after CT (computed tomography) simulation in a
supine position with customized immobilization devices to
decrease variability in the daily setup. The planning target volumes
and clinical target volumes were deﬁned and contoured on the
individual axial CT slices according to the guideline report from
Small et al8 for vaginal and nodal areas. A seven ﬁeld equally spaced
co-planner IMRT plan was generated using the dose-volume con-
straints described by RTOG 04138. A patient whose disease was
limited to  IB2 received 50.4 Gy in 28 fractions over 5.5 weeks to
the vaginal planning-target-volume (PTV) and nodal PTV. Patients
with locally advanced diseases received 60 Gy in 30 fractions over 6
weeks to the gross tumor volume deﬁned by the computed
tomographic simulation after discussion with the radiologist, and
50.4 Gy in 30 fractions to the vaginal PTV and nodal PTV at the same
time by using the simultaneous integrated boost technique. The
prescription dose was the isodose which encompassed at least 97%
vaginal PTV and nodal PTV. No more than 20% of any PTV received
> 110% of its prescribed dose. No more than 1% of any PTV received
< 93% of its prescribed dose. No more than 1% or 1 cc (whichever is
smaller) of the tissue outside the PTVs received > 110% of the dose
prescribed to the primary PTV. Normal tissues were strongly
encouraged to remain within these limits: small bowel volume 
30% to receive 40 Gy, rectum volume  35% to received 50 Gy,
bladder volume 35% to receive 50 Gy, and femoral head volume
20% to receive  30 Gy. The isocenter was placed at the geometric
center of the PTV. Orthogonal electronic portal images were taken
weekly to verify the setup accuracy.
All patients received high dose rate iridium-192 brachytherapy
after whole pelvic irradiation. Brachytherapy was delivered to point
A at a total dose of 20e30 Gy in 4e6 fractions, twice a week, for a
minimum cumulative external and intracavitary dose of 85 Gy and
a maximal dose of 95 Gy. We used Henschke shielded afterloading
applicators, set number 084400 (Radiation Products Design, Inc.,
Albertville, MN, USA) and iridium-192 for the isotope seed (Le
Petten, North Holland, The Netherlands). Treatment was planned
using the Plato Brachytherapy planning system version 14.2.4
(Nucletron International B.V., Veenendaal, The Netherlands).
All patients received at least 45 Gy in the whole pelvis, but none
received more than 50.4 Gy. We attempted to complete the entire
course of CCRT within 8 weeks, but chemotherapy was withheld if
the neutrophil count was < 1500 cells/dL or the platelet count was
< 10,000 cells/dL. In cases with Grade 3 hematologic or non-
hematologic toxicity and decreased performance status, radio-
therapy was halted until recovery of performance status.
Eligibility criteria for administration of chemotherapy included
a serum creatinine level of < 1.5 mg/dL, absolute neutrophil count
of > 1500 cells/dL, and a platelet count of > 100,000 cells/dL.
Cisplatin (Fresenius KABI, Maharashtra, India) was administered
beginning on the 1st day of radiation at a dose of 40 mg/m2 weekly,
no more than 70 mg per dose, up to six doses. Cisplatin was
withheld if the absolute neutrophil count was < 1000 cells/L,
creatinine level > 2.0 mg/dL, or platelet count < 75,000 cells/dL.
Patients were given transfusions with packed red blood cells to
maintain a hemoglobin level > 10 g/L during CCRT.
Chart review was used for toxicity analyses. Acute toxicities
were graded weekly according to the National Cancer Institute
Common Toxicity Criteria version 3.0. Chronic toxicities were
graded weekly according the American Radiation Therapy
Oncology Group criteria. Gastrointestinal, genitourinary, and he-
matological complications are among the most common undesir-
able side effects for patients treated with pelvic RT. A maximal
grade of toxicities was recorded for statistical analysis.
After completion of treatment, patients received regular follow-
up every 1e2 months in the 1st year, then every 3 months
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were calculated from the date of treatment. Surviving patients
were censored on the date of last follow-up. We conﬁrmed the
cause of death by correspondence, telephone, or medical record
review.
All data were analyzed with the SPSS program for Windows
(version 13; IBM, Armonk, NY, USA). We used Pearson Chi-square
test to ﬁnd the signiﬁcance of between-group differences in
treatment groups and t tests for ﬁnding the signiﬁcance of mean
between groups. The Kaplan-Meier method compared by the log-
rank test was used for OS and DFS. A p value  0.05 was consid-
ered signiﬁcant, and only two-sided results with assumed equal
variance were used.
3. Results
The patient and tumor characteristics of these groups are
summarized in Table 1. Conventional 2D radiotherapy was received
in 30 patients (2D-CCRT-group) and intensity-modulated radio-
therapy was received in 30 patients (IM-CCRT-group). The median
and mean follow-up durations of all patients were 41.7 months and
42.6 months (range, 1e101 months). The median age of patients in
the IM-CCRT group was greater (80.5 years vs.77.8 years,
p ¼ 0. 0044). There was no statistical difference in combined
medical problems such as diabetes, hypertension, atherosclerosis,
and chronic renal failure between the two groups. There was no
statistical difference in histological type, The International Feder-
ation of Gynecology and Obstetrics (FIGO) stage, and performance
status between the two groups. About 30% patients had diabetes,
hypertension, or both. There were fewer patients with medical
problems in the IM-CCRT-group, but not signiﬁcantly. Only two
cases with adenocarcinoma were noted in the IM-CCRT-group in
this analysis. Around 60% patients had performance status one in
both groups (p ¼ 0.793). The clinical stage distribution was iden-
tical in both groups (p ¼ 0.796) and about half of patients were
staged as having locally advanced disease.
There was no statistical difference in receiving cycles of
chemotherapy between the two groups (p ¼ 0.161). More cycles ofTable 1
Characteristics between patients who received two-dimensional concurrent chemo-
radiotherapy (2D-CCRT) and intensity-modulated concurrent chemo-radiotherapy
(IM-CCRT).
2D-CCRT
(n ¼ 30)
IM-CCRT
(n ¼ 30)
p
Age (y) Median 77.8 (75e88) 80.5 (75e88) 0.044
Medical problems Diabetes 7 (23) 5 (17) 0.643
Hypertension 11 (37) 6 (20) 0.152
Atherosclerosis 6 (20) 1 (3.3) 0.085
Histology SCC 30 (100) 28 (93.3) 0.554
Ad-CA 0 2 (6.7)
ECOG-PS 0 12 (40) 13 (43) 0.793
1 18 (60) 17 (57)
FIGO stage IB1-2-IIA 16 (53) 15 (50) 0.796
IIB-IVB 14 (47) 15 (50)
Cycles of chemotherapy One 2 (6.7) 4 (13.3) 0.161
Three 1 (3.3) 3 (10)
Four 4 (13.3) 9 (33.3)
Five 8 (27) 7 (23.3)
Six 15 (50) 7 (23.3)
Total treatment
duration (d)
Mean (SD) 51.7 (± 8.6) 66.1 (± 6.2) 0.000
 56 24 (80) 2 (6.7)
> 56 6 (20) 28 (93.3)
Data are presented as n (%) or n (range).
2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; Ad-
CA ¼ adenocarcinoma; ECOG-PS ¼ Eastern Cooperative Oncology Group-Perfor-
mance Status; FIGO ¼ The International Federation of Gynecology and Obstetrics;
IM-CCRT ¼ intensity-modulated concurrent chemo-radiotherapy; SCC ¼ squamous
cell carcinoma; SD ¼ standard deviation.chemotherapy were given in the 2D-CCRT-group than in the IM-
CCRT-group.
Only two cases in IM-CCRT completed their treatment in 8
weeks, but 24 cases in 2D-CCRT completed their treatment in 56
days (p < 0.05). The mean treatment duration was signiﬁcantly
longer for IM-CCRT patients than for 2D-CCRT patients (66.1 days
vs. 51.7 days, p < 0.05).
Up to December 2014, eight patients in the 2D-CCRT-groupwere
lost, and nonewere lost in the IM-CCRT-group. The mean follow-up
durations were the same in these groups (41.4 months vs. 43.7
months, p ¼ 0.729). One case in the IM-CCRT group had local
recurrence with distant metastasis. The local recurrence and
distant metastasis were signiﬁcantly lower for the IM-CCRT-group
than for the 2D-CCRT-group (local recurrence ¼ 1/30 vs. 7/30,
p ¼ 0.023; distant recurrence ¼ 1/30 vs. 9/30, p ¼ 0.006). About
30% of cases died and the incidences were identical for these two
groups (8/30 vs. 11/30, p ¼ 0.405). No cancer related death was
noted in the IM-CCRT-group (0/30 vs. 6/30).
Table 2 summarizes the frequency and severity of acute
complication rates. Acute toxicities such as diarrhea, abdominal
cramping, nausea, anemia, leukocytopenia, urinary tract infection,
and dysuriawere observed in this study. The chronic toxicities were
mainly proctitis and cystitis. Acute Grade 2 and Grade 3 gastroin-
testinal toxicities tended to be more signiﬁcant in the IM-CCRT-
group (2D-CCRT vs. IM-CCRT: Grade 2 ¼ 23% vs. 27%, Grade
3 ¼ 23% vs. 37%, p ¼ 0. 001). Acute genitourinary and hematologic
toxicities were common with no differences in both groups
(p ¼ 0.502, p ¼ 0.338).
The chronic toxicities in these two groups are summarized in
Table 3. Higher chronic gastrointestinal toxicity was noted in the
IM-CCRT-group, but the p value was not signiﬁcant (2D-CCRT vs.
IM-CCRT: Grade 2 ¼ 17% vs. 23.3%, Grade 3 ¼ 0% vs. 13.3%,
p ¼ 0.054). Chronic genitourinary toxicity was higher in patients
receiving 2D-CCRT, but the p value was not signiﬁcant (2D-CCRT vs.
IM-CCRT: Grade 2 ¼ 13.3% vs. 6.7%, Grade 3 ¼ 3.3% vs. 0%, respec-
tively, p ¼ 0.083).
The DFS and OS of the entire group are shown in Figure 1. The 3-
year OS of the 2D-CCRT-group and IM-CCRT-group were 70.2% and
78.8%, respectively. The 3-year DFS of the 2D-CCRT-group and IM-
CCRT-group were 73.4% and 100%, respectively. The mean OS for
patients in the 2D-CCRT-group and in the IM-CCRT-group were 69
months and 66 months, respectively. The mean DFS for patients in
the 2D-CCRT-group and in the IM-CCRT-group were 79.86 months
and 78.64 months, respectively. Patients who had IM-CCRT had
better DFS then 2D-CCRT cases (p ¼ 0.014). The OS is identical in
both groups (p ¼ 0.689).
4. Discussion
Optimal cancer treatment among the elderly is controversial.
Currently, those patients with cervical and ovarian cancer are re-
ported to receive less aggressive treatment when general perfor-
mance, comorbidity, and treatment tolerance are taken into
consideration9,10. Our previous study revealed 2D radiotherapy
with concurrent cisplatin chemotherapy was well tolerated in
elderly patients with good performance. Although higher treat-
ment related acute and chronic toxicities were noted, elderly pa-
tients with cervical cancer had a better overall outcome following
chemoradiotherapy then radiation alone or incomplete
radiotherapy4.
IMRT alone has been documented with lower treatment related
toxicity and better tumor control than conventional radiotherapy
alone6,7,11. There are many dosimetric studies that show a reduction
of dose delivered to the pelvic organs-at-risk with IMRT compared
with conventional RT in the treatment of cervical cancer12e14.
Figure 1. KaplaneMeier survival curves of patients stratiﬁed by treatment received.
(A) Overall survival (p ¼ 0.689), (B) disease-free survival (p ¼ 0.014).
Table 2
Incidence of acute toxicities in both groups.
Grade 2D-CCRT IM-CCRT p
Gastrointestinal (no.) 0e1 17 (57) 11 (37) 0.001
2 6 (20) 8 (27)
3 7 (23) 11 (37)
Genitourinary (No.) 0e1 27 (90) 29 (96.7) 0.502
2 3 (10) 1 (3.3)
Hematologic (No.) 0e1 20 (67) 25 (83) 0.338
2e3 10 (33) 5 (17)
Data are presented as n (%).
2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; IM-CCRT ¼ inten-
sity-modulated concurrent chemo-radiotherapy.
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rectal and cystic toxicity11. In the present study, acute gastrointes-
tinal toxicity and chronic gastrointestinal toxicity seemed higher in
the IM-CCRT group. By reviewing IMRT planning, “hot spots” with
high rectum and bladder volumes were sometimes unavoidable.
This uncertain high dose would elevate the highest dose to the
rectum and bladder. The difference in acute and chronic genito-
urinary toxicities between the groups was not signiﬁcant (acute:
10% vs. 3%, p ¼ 0.52; chronic: 16.6% vs. 6.7%, p ¼ 0.083). For the
bladder, the high dose volume ratio might not be high enough to
produce a higher incidence of toxicity. However, for the rectum, this
might be the cause of higher toxicity. This phenomenon might be
exaggerated in the elderly because of more complex comorbidity
and the combination of CCRT. Therefore, the guideline related to
dose-volume constrains might need to be modiﬁed for the elderly.
Further dose-volume study will be needed to address this question.
Hasselle et al6 reported the results of 111 patients with Stage
IeIVA cervical carcinoma treated with IMRT. The 3-year OS was
78%. Du et al11 reported their comparison results of 122 patients
with IMRT and conventional radiotherapy and the 3-year OS was
82.5% for patients treated with IMRT and concurrent chemotherapy
and the complete response rate was 88% for IMRT cases11. In the
present study, the 3-year actuarial OS of the IM-CCRT group was
78.8%. That means for the elderly patients with cervical cancer,
aggressive treatment did not shorten their survival by comparing
with the general population, even though higher gastrointestinal
toxicity had been noted in our study.
A population-based study from Taiwan concluded that three-
dimensional conformal radiotherapy had better OS than 2D radio-
therapy after adjustment for age, diabetes mellitus, hypertension,
coronary heart disease, hyperlipidemia, side effects, urbanization
level, geographic region, and enrollee category (5-year survival
rate: 82.3% vs. 73%, p ¼ 0.007, the hazard ratio ¼1.82 with CI,
1.16e2.85)15. In our study, the 3-year progression-free survival of
the IM-CCRT group was 100%. IM-CCRT did provide better 3-year
DFS than 2D-CCRT, but the OS did not conclude in signiﬁcant
improvement by using IM-CCRT. Five deaths in the IM-CCRT group
were not related to their cancers (1 with pneumonia, 2 with severeTable 3
Incidence of chronic toxicities in both groups.
Grade 2D-CCRT IM-CCRT p
Gastrointestinal (No.) 0e1 25 (83) 19 (63.3) 0.054
2 5 (17) 7 (23.3)
3 0 (0) 4 (13.3)
Genitourinary (No.) 0e1 25 (83) 28 (93.3) 0.083
2 4 (13.3) 2 (6.7)
3 1 (3.3) 0 (0)
Data are presented as n (%).
2D-CCRT ¼ two-dimensional concurrent chemo-radiotherapy; IM-CCRT ¼ inten-
sity-modulated concurrent chemo-radiotherapy.anemia, 2 with urosepsis). Causes of the other three deaths in the
IM-CCRT group were unknown, but two patients developed other
cancers during follow-up.
Prolonged treatment times in cervical cancer treated with
conventional radiotherapy were reported with poor pelvic control
and cancer-speciﬁc survival in several retrospective studies16,17.
Song et al17 reported that total treatment time over 56 days was not
signiﬁcantly affected by pelvic failure, distant failure, and disease
speciﬁc mortality for cervical cancers treated with concurrent
chemoradiotherapy. Reasons for treatment prolongation were
multifactorial. The incidence of Grade 3þ acute toxicities and
delayed timewith brachytherapy were reported in analysis by Song
et al17. The incidence of Grade 3 acute gastrointestinal toxicities was
signiﬁcantly higher in the IM-CCRT group in our study and the fact
that we started brachytherapy after the completion of IMRT might
be the major reason for a prolonged treatment time. In our study,
93.3% of patients who received IM-CCRT had a prolonged treatment
time over 56 days. The disease speciﬁc survival and OS were not
affected by this factor, most likely because there were other
modulating factors that affect outcome, such as more adequate
tumor coverage with higher dose by IMRT than 2D, beneﬁts of
concurrent chemotherapy, and a physician’s threshold for giving RT
breaks for toxicities. The study published by Petereit et al16 which
mentioned a treatment range of 43e80 days yielded a signiﬁcant
difference in cell kill, particularly with shorter tumor doubling
time; in addition, repopulation of proliferating tumor clonogens in
cervical cancer may partially be negated by higher radiation doses.
Therefore, in the IM-CCRT group, prolonged treatment time might
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domized trials will be arranged to address these results.
We acknowledge that this study has several limitations. First,
the patient sample size is small in this retrospective study and the
mean follow-up period is short. Reasons for the short follow-up
were multifactorial. Old age, family care, and comorbidity may be
related to the short follow-up. However, in this study the mean
follow-ups in both groups were > 36 months, therefore we felt that
the relatively short follow-up does not compromise the analysis for
DFS. Second, the comorbid conditions inﬂuencing survival may be
underestimated, such as diabetes may be a pretreatment prog-
nostic factor in survival of cervical cancer15.
Our study suggested that IM-CCRT is feasible for elderly patients
with cervical cancer but there should be caution in its application.
IM-CCRT signiﬁcantly increased acute gastrointestinal toxicities
with encouraging preliminary clinical results compared with 2D-
CCRT. Prolonged treatment time had no negative impact on tumor
control in the IM-CCRT group. Large sample prospective clinical
trials are needed to evaluate the beneﬁts of IM-CCRT for cervical
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